Table 3.
Results of the base-case analysis of patients with moderate to severe UC and CD in the United Kingdom and France.
| Sequence | Ulcerative Colitis | Crohn’s Disease | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cost | QALY | Incremental Costs* | Incremental QALYs* | ICER | Cost | QALY | Incremental Costs* | Incremental QALYs* | ICER | |
| UK | ||||||||||
| Sequence 1: infliximab → vedolizumab → surgery | £59,605.74 | 6.0266 | –£1767.01 | 0.0241 | Dominant | £72,166.04 | 4.8202 | £17,243.49 | 0.5500 | £31,349.42 |
| Sequence 2: vedolizumab → infliximab → surgery | £61,372.74 | 6.0025 | – | – | – | £54,922.55 | 4.2702 | – | – | – |
| Sequence 3: infliximab → adalimumab → vedolizumab → surgery | £58,367.32 | 6.0627 | –£6580.01 | 0.0211 | Dominant | £77,849.41 | 4.9715 | £14,850.32 | 0.4875 | £30,463.88 |
| Sequence 4: vedolizumab → infliximab → adalimumab → surgery | £64,947.32 | 6.0416 | – | – | – | £62,999.09 | 4.4841 | – | – | – |
| France | ||||||||||
| Sequence 1: infliximab → vedolizumab → surgery | €41,778.44 | 6.0515 | –€3099.32 | 0.0242 | Dominant | €116,980.61 | 4.8396 | –€6181.45 | 0.5522 | Dominant |
| Sequence 2: vedolizumab → infliximab → surgery | €44,877.76 | 6.0273 | – | – | – | €123,162.06 | 4.2873 | – | – | – |
| Sequence 3: infliximab → adalimumab → vedolizumab → surgery | €41,778.16 | 6.0879 | –€6922.34 | 0.0212 | Dominant | €118,123.44 | 4.9916 | –€6686.41 | 0.4896 | Dominant |
| Sequence 4: vedolizumab → infliximab → adalimumab → surgery | €48,700.49 | 6.0666 | – | – | – | €124,809.85 | 4.5021 | – | – | – |
*Incremental costs, incremental QALYs of sequence 1 compared with sequence 2, and sequence 3 compared with sequence 4.
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.